Seeing a terminated clinical trial feels like a verdict on the science, and it usually is not one. Termination is a registry status with a narrow definition and a required public explanation. This article covers what stopping early involves and what the label does not tell you.
TLDR: Terminated means a study stopped early and will not start again. Withdrawn means it stopped before enrolling anyone. Suspended means it stopped but may start again. Monitoring boards, funding gaps, and slow enrollment all end studies, and federal rules require a status update within 30 calendar days plus a stated reason. Most terminations mean the trial could not answer its question, not that people were harmed. Banking adipose tissue is preservation only. It is not tied to any single study and does not guarantee eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat is a tissue preservation connector service, not a medical practice or a research sponsor. It does not provide FDA-approved treatments or cures, and it does not guarantee eligibility, access, or clinical benefit from any trial, pathway, or future use. Adipose tissue, the stromal vascular fraction, and adipose-derived cells are investigational and are not FDA approved. This article explains public registry mechanics for educational purposes only, and readers should consult their own licensed healthcare professionals before making decisions about banking, treatment, or research participation.
People who follow adipose-derived cell research learn to check ClinicalTrials.gov. Then a study they have been watching flips to Terminated, and the reaction is immediate. Something must have gone wrong. Someone must have been hurt.
Sometimes that is true. More often it is not. Studies stop because money ran out, because enrollment stalled, or because a planned statistical check said the trial was unlikely to answer its own question. One word on a status line does not separate those situations.
The useful part is that the reason is almost always written down, because federal rules require sponsors to post one.
What a terminated clinical trial actually means
Three registry statuses get confused constantly, and the mix-up changes how a study reads. The ClinicalTrials.gov glossary defines each one precisely. The exact wording removes most of the guesswork.
| Registry status | Official definition | What it tells a reader |
|---|---|---|
| Terminated | “The study has stopped early and will not start again. Participants are no longer being examined or treated.” | Over for good. The reason sits in a separate field. |
| Withdrawn | “The study stopped early, before enrolling its first participant.” | No one enrolled, so no participant data exists. |
| Suspended | “The study has stopped early but may start again.” | A pause, not an ending. |
| Completed | “The study has ended normally, and participants are no longer being examined or treated (that is, the last participant’s last visit has occurred).” | Finished as planned. The answer can still be negative. |
None of those definitions mentions safety, harm, or benefit. They describe process, not findings, so a status line is never a scientific conclusion.
Who stops a trial, and what triggers the decision
Trials do not stop by accident. A specific party makes the call, under rules written before enrollment began.
A monitoring board at a planned interim analysis
Larger studies appoint an independent data and safety monitoring board. It reviews accumulating data at checkpoints set in advance, sees what investigators cannot see while the study is blinded, and can recommend halting randomization.
Boards halt for two very different reasons. One is safety, where the data suggest participants are at risk. The other is futility, where the trial is on track to miss the effect it was designed to detect, so continuing adds risk without adding an answer. Both produce a Terminated status. Only one involves harm.
Sponsors, funding, and enrollment
Most terminations never reach a monitoring board. Grants end. A company reprioritizes or runs short of capital. A single-site study cannot recruit enough participants and closes years behind schedule. These are administrative endings, not scientific ones.
The rule that puts the reason on the public record
United States trial transparency rests on the federal results reporting rule at 42 CFR Part 11, issued by NIH and HHS. Sponsors register a covered study within 21 days of first enrollment and post results within a year of primary completion.
Stopping does not end that duty. Under 42 CFR 11.64, a status change must be updated within 30 calendar days, and a “why study stopped” entry is required whenever a study is suspended, terminated, or withdrawn. The section also requires earlier information to stay publicly available, so updates add to the record rather than erase it.
History does not vanish. The ClinicalTrials.gov about page states, “Information about each study is permanently available in the database, even after the study ends.”
A worked example: why NCT04371393 stopped
NCT04371393 was a Phase 3 study of mesenchymal stromal cells in moderate to severe COVID-19 acute respiratory distress syndrome, run by the Icahn School of Medicine at Mount Sinai with Mesoblast and NHLBI. It randomized remestemcel-L against placebo at 21 United States sites, enrolled 223 participants, and is Terminated.
The stated reason, quoted from the registry record for NCT04371393, reads: “At 3d interim analysis, randomization, but not follow-up, was halted by the DSMB due to low predictive probability of achieving postulated mortality benefit (pre-specified 42.5% relative mortality reduction) were the trial to complete randomization.”
Every clause matters. A monitoring board acted at a scheduled interim analysis. It halted randomization but not follow-up, so enrolled participants were still followed. That is a futility stop, not a safety scandal, and the distinction is the whole point.
The same cell product later cleared a different bar. Remestemcel-L was approved on December 18, 2024 as the first FDA-approved mesenchymal stromal cell therapy, for steroid-refractory acute graft versus host disease in pediatric patients 2 months of age and older. One terminated study did not settle its fate.
Two adipose and MSC specific terminations
Adipose research has its own examples. NCT01676441, sponsored by Pharmicell in South Korea, studied autologous mesenchymal stem cells in chronic spinal cord injury as a Phase 2/3 trial and is Terminated with 20 participants. NCT03269409, a Mayo Clinic Phase 1 study of adipose-derived regenerative cells in bilateral femoral head osteonecrosis, is Terminated with 8 participants.
Neither number explains itself. A small final count fits a recruitment problem, a funding problem, or an early stopping decision equally well. Read the stated reason instead of inferring one.
The other failure mode: a completed trial that answered no
Termination is not the only way research disappoints. ADIPOA2, NCT02838069, was a Phase 2b trial led by University Hospital Montpellier. It tested a single intra-articular knee injection of culture-expanded autologous adipose-derived MSCs against placebo in mild to moderate knee osteoarthritis, and it completed.
The result was negative. In the published ADIPOA2 results in Annals of the Rheumatic Diseases in December 2025, 47.3 percent of cell-treated patients versus 54.8 percent of placebo patients were strict OARSI/OMERACT responders at six months, a relative risk of 0.86. The placebo arm was numerically higher. The authors concluded that a single intra-articular injection “did not significantly improve pain and function.” The publication reports 97 patients analyzed.
Put the two side by side and the lesson lands. One stopped early and produced no answer. One finished and produced an answer nobody wanted. An honest picture includes both, and marketing that quotes only recruiting studies tells half the story.
How to read a stopped trial without overreacting
Start with the record. Read the “why study stopped” text, then check the phase, actual enrollment against the original estimate, and whether results were posted. Knowing what clinical trial phases measure keeps a stopped Phase 1 safety study from looking like a failed efficacy program.
Then widen the view. One termination matters less in a field with many ongoing studies, so check which active adipose trials are still enrolling and how to find legitimate trials. The FDA consumer alert on regenerative medicine products sets the baseline: blood-forming stem cells from cord blood are the only approved stem cell products, and no exosome product is FDA approved.
What a terminated trial means for banked adipose tissue
Nothing, in the direct sense. Banking is preservation. Tissue in storage is not enrolled in a study, not assigned to a protocol, and not dependent on one sponsor staying funded. When a study stops, stored tissue is unaffected.
The second half matters just as much. Banking does not guarantee eligibility, access, or clinical benefit, and it never did. Any future use depends on FDA regulatory status at that time, a physician’s judgment, and whether an approved or investigational pathway exists. A terminated trial removes no promise, because none was made.
Frequently Asked Questions
What are the common reasons a clinical trial is terminated before completion?
Funding ends, enrollment falls short, a site or sponsor withdraws, or an independent monitoring board halts randomization at a planned interim analysis for safety or for futility. Federal rules require a “why study stopped” entry, so the specific reason is usually stated on the registry page.
Does early termination always mean the treatment is unsafe?
No. Safety is one reason among several, and not the most common. NCT04371393 was terminated because a monitoring board found a low predictive probability of achieving the postulated mortality benefit, which is futility rather than harm. Termination usually means a trial could not answer its question.
What happens to participants already enrolled if a trial stops?
It depends on the study, and the record often says. In NCT04371393, randomization was halted while follow-up continued, so enrolled participants were still monitored. The glossary notes that participants are no longer being examined or treated once a study closes. Anyone affected should ask the investigators directly about follow-up.
How is termination different from a trial being suspended or withdrawn?
The glossary separates them cleanly. Terminated means the study stopped early and will not start again. Suspended means it stopped early but may start again. Withdrawn means it stopped before enrolling its first participant, so no participant data exists. Only Suspended leaves room to resume.
Where can patients see if a specific trial was terminated and why?
On the study’s own ClinicalTrials.gov page. Search the NCT number, check the status field, and read the “why study stopped” entry. A status change must be posted within 30 calendar days, and information about each study stays permanently available even after it ends.
Does a terminated trial affect adipose tissue that is already banked?
No. Banked tissue is preserved material, not study material, and is not tied to any single trial or sponsor. A study stopping does not change stored tissue. Banking also does not guarantee eligibility, access, or clinical benefit, so a termination removes nothing. Future use depends on FDA status and physician guidance.
Key Takeaways
Terminated, withdrawn, and suspended are three different facts that readers collapse into one worry. Terminated means a study stopped early and will not start again. Withdrawn means it never enrolled anyone. Suspended means it may resume. The reason is rarely a mystery, because 42 CFR 11.64 requires a status update within 30 calendar days and a stated explanation for all three.
NCT04371393 shows the pattern. A monitoring board halted randomization at a planned interim analysis for low predictive probability of the postulated mortality benefit, a futility stop rather than a safety scandal, and follow-up continued. ADIPOA2 shows the other failure mode, a completed trial reporting no significant improvement in pain and function against placebo. Termination is not proof that a cell therapy is dangerous, and it is not proof that it works. Adipose-derived cells remain investigational, the evidence is preliminary, and decisions belong with a licensed provider.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Anyone considering adipose tissue banking for potential future use can review current pricing and bring questions to a licensed provider first. The team is reachable through the contact page.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about banking, treatment, or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: adipose stem cell trials.
